Abstract
Struma ovarii is a rare monodermal ovarian teratoma in which thyroid tissue is the predominant or exclusive element. Malignant transformation is known to occur, usually as classical papillary thyroid carcinoma (PTC). However, the recognition of follicular variant PTC raises the possibility of similar malignancy arising in struma ovarii. We examined 13 cases of struma ovarii to determine if these lesions can exhibit histological, immunohistochemical, and/or molecular features of follicular variant PTC. Ten of these had atypical histology, cytologic features of PTC, and all ten showed diffuse positivity for CK19; eight of these were also positive for HMBE-1. Mutational analysis for BRAF identified no V600E mutations. However, seven of the ten cases with features of follicular variant PTC exhibited a rearranged in transformation (RET)/PTC rearrangement by reverse transcriptase polymerase chain reaction (RT-PCR). The three cases considered to be benign based on histologic and cytologic criteria were negative for CK19 and HBME-1 by immunohistochemistry, and had no evidence of BRAF mutation or ret/PTC-1 and ret/PTC-3 rearrangements. These results indicate that follicular variant PTC can occur in struma ovarii and that such lesions exhibit the same morphologic and immunohistochemical profile as follicular variant PTC in thyroid. The application of molecular testing to verify the diagnosis can be valuable, as these lesions may harbor ret/PTC gene rearrangements.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Scully R, Young R, Clement P. Tumors of the ovary, maldeveloped gonads and fallopian tubes. Atlas of tumor pathology, third series, fascicle. Washington, D.C.: Armed Forces Institute of Pathology, 1996.
Roth LM, Talerman A. The enigma of struma ovarii. Pathology 39(1):139–46, 2007.
Devaney K, Snyder R, Norris HJ, Tavassoli FA. Proliferative and histologically malignant struma ovarii: a clinicopathologic study of 54 cases. Int J Gynecol Pathol 12(4):333–43, 1993.
McDougall IR. Metastatic struma ovarii: the burden of truth. Clin Nucl Med 31(6):321–4, 2006.
Bolat F, Erkanli S, Kayaselcuk F, Aslan E, Tuncer I. Malignant struma ovarii: a case report. Pathol Res Pract 201(5):409–12, 2005.
Makani S, Kim W, Gaba AR. Struma Ovarii with a focus of papillary thyroid cancer: a case report and review of the literature. Gynecol Oncol 94(3):835–9, 2004.
Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Path 14(4):338–42, 2001.
Cheung CC, Ezzat S, Ramyar L, Freeman JL, Asa SL. Molecular basis of Hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab 85(2):878–82, 2000.
Cheung CC, Boerner SL, MacMillan CM, Ramyar L, Asa SL. Hyalinizing trabecular tumor of the thyroid: a variant of papillary carcinoma proved by molecular genetics. Am J Surg Pathol 24(12):1622–6, 2000.
Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28(10):1336–40, 2004.
Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said MS, Haugen BR. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol 122(4):524–31, 2004.
Volante M, Bozzalla-Cassione F, DePompa R, Saggiorato E, Bartolazzi A, Orlandi F, et al. Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Arch 445(2):183–8, 2004.
Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6(4):292–306, 2006.
Cheung CC, Carydis B, Ezzat S, Bedard YC, Asa SL. Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metab 86(5):2187–90, 2001.
Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio A, Fagin JA, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 89(10):5175–80, 2004.
Papotti M, Volante M, Giuliano A, Fassina A, Fusco A, Bussolati G, et al. RET/PTC activation in hyalinizing trabecular tumors of the thyroid. Am J Surg Pathol 24(12):1615–21, 2000.
Schmidt JF, Heinrich M, Derr V, Corless CL, Fletcher JA, Nose V. BRAF, RAS, and RET mutations in malignant struma ovarii: a comparative study with benign struma ovarii. Mod Path 18(Suppl 1):945, 2005.
Flavin R, Smyth P, Crotty P, Finn S, Cahill S, Denning K, et al. BRAF T1799A mutation occurring in a case of malignant struma ovarii. Int J Surg Pathol 15(2):116–20, 2007.
Elisei R, Romei C, Castagna MG, Lisi S, Vivaldi A, Faviana P, et al. RET/PTC3 rearrangement and thyroid differentiation gene analysis in a struma ovarii fortuitously revealed by elevated serum thyroglobulin concentration. Thyroid 15(12):1355–61, 2005.
LiVolsi VA. Surgical pathology of the thyroid. Philadelphia: Saunders, 1990.
DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs. WHO classification of tumours. Lyons, France: IARC Press, 2004.
DeSimone CP, Lele SM, Modesitt SC. Malignant struma ovarii: a case report and analysis of cases reported in the literature with focus on survival and I131 therapy. Gynecol Oncol 893:543–8, 2003.
Rosenblum NG, LiVolsi VA, Edmonds PR, Mikuta JJ. Malignant struma ovarii. Gynecol Oncol 32(2):224–7, 1989.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Boutross-Tadross, O., Saleh, R. & Asa, S.L. Follicular Variant Papillary Thyroid Carcinoma Arising in Struma Ovarii. Endocr Pathol 18, 182–186 (2007). https://doi.org/10.1007/s12022-007-0022-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12022-007-0022-8